MedTrace Logo

SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer

NCT02970682 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-07-12

No results posted yet for this study

Summary

This is a Phase 2 study to demonstrate the safety and efficacy of SFX-01 when used in combination with aromatase inhibitors (AIs), tamoxifen and fulvestrant.

Patients will be enrolled into one of three study arms (SFX-01 in combination with AI, tamoxifen or fulvestrant) based on their current therapy.

Conditions

  • Breast Neoplasm

Interventions

DRUG

SFX-01

Stabilised Sulforaphane

DRUG

Fulvestrant

Fulvestrant

DRUG

Tamoxifen

Tamoxifen

DRUG

Aromatase Inhibitors

Sponsors & Collaborators

  • Premier Research Group plc

    collaborator UNKNOWN

  • Evgen Pharma

    lead INDUSTRY

Principal Investigators

  • Sacha Howell, MD PhD · The Christie NHS Foundation Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2019-01-31
Completion
2019-03-31

Countries

  • Belgium
  • France
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02970682 on ClinicalTrials.gov